TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Cytologically confirmed acute myeloid leukemia (AML) in first complete remission (CR) or subsequent CR Less than 5% blasts in normal bone marrow Less than 3 months since last dose of chemotherapy OR Less than 6 months since achieving CR~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 OR Karnofsky 70-100% Life expectancy: Greater than 3 months Hematopoietic: WBC at least 1,500/mm3 Platelet count at least 75,000/mm3 Hepatic: PTT normal Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT and SGPT no greater than 2 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No class III or IV heart disease No hypotension, severe hypertension, or serious or uncontrolled cardiac dysrhythmia (e.g., ventricular arrhythmias) No acute myocardial infarction within the past 12 months No active uncontrolled angina pectoris No symptomatic arteriosclerotic blood vessel disease Pulmonary: No history of asthma within the past 5 years Other: No other active malignancies except localized basal or squamous cell skin cancer or carcinoma in situ of the cervix HIV negative No prior or active peptic or esophageal ulcer disease No history of hypersensitivity to histamine or histamine products, or severe allergies Not pregnant or nursing~PRIOR CONCURRENT THERAPY: Biologic therapy: Prior autologous stem cell transplantation allowed No prior allogeneic stem cell transplantation No other concurrent immunomodulating agents Chemotherapy: See Disease Characteristics Prior induction or consolidation therapy allowed No concurrent chemotherapy Endocrine therapy: At least 24 hours since prior corticosteroids No concurrent steroids Radiotherapy: Not specified Surgery: Not specified Other: No concurrent alternative therapy (e.g., laetrile, Brudzinski's treatment, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • All women at term(\>or =37 weeks of gestation)~  * Healthy~ * American Society of Anesthesiologists(ASA) class1 and 2~ * Women undergoing non-elective caesarean section whose anesthetic plan is for spinal anesthesia with bupivacaine and fentanyl~Exclusion Criteria:~* • Women with American society of anesthesiologist physical status\>2~  * Body mass index \>or =40 kg per square meter~ * Height \<150 cm~ * Any contraindication to the spinal anesthesia~ * History of substance abuse~ * History of hallucinations~ * Chronic opioid therapy~ * Chronic pain or on any pain medication currently~ * Patient with maternal complications,like cardiovascular disease pre-eclampsia,diabetes,multiple gestation,known fetal abnormality~ * Cases with severely compromised fetus where immediate administration of general anesthesia is required.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- analgesic effects of ketamine (Type: EXPERIMENTAL): the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
- placebo (Type: PLACEBO_COMPARATOR): they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interventions for Unemployed Hazardous Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-65 years~* not worked for pay in the formal economy for \>4 weeks~* willing to participate in a workforce training program and willing to accept either part-time or full-time work~* hazardous alcohol use defined by AUDIT scores \>8, a mean of \>2 drinks/drinking day or \>14 drinks/week in men (\>1 drink/drinking day or \>7 drinks/week in women) in the past 2 months, or submission of an alcohol positive breathalyzer (\>0.02 g/dl) or EtG positive urine sample~* English or Spanish speaking and able to read at 5th grade level~* have a valid photo ID~* willing and able to use study equipment and sign an off-campus property transfer form~Exclusion Criteria:~* have begun receiving unemployment benefits within the past 4 weeks~* worked full- or part-time \<3 months in the past 3 years in the formal or informal economy~* physiological alcohol withdrawal symptoms (score \>10 on Clinical Institute Withdrawal Assessment for Alcohol-revised)~* physiological withdrawal symptoms from an illicit drug use disorder~* serious untreated psychiatric illness~* in recovery from gambling disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- job activity contracting (Type: ACTIVE_COMPARATOR): Standard services plus job activity contracting and alcohol monitoring
- reinforcement for negative alcohol samples (Type: EXPERIMENTAL): Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
- reinforcement for completing activities (Type: EXPERIMENTAL): Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
- reinforcement for negative alcohol samples & activities (Type: EXPERIMENTAL): Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old, who must understand and voluntarily sign an Informed Consent.~* Patients must have documented diagnosis of Multiple Myeloma and have measurable disease.~* Patients must have undergone prior treatment with ≥ 2 treatments lines, of anti-myeloma therapy.~* Patients must have either refractory or relapsed and refractory disease.~* Patients must have received at least 2 consecutive cycles of prior treatment that include lenalidomide and bortezomib, either alone or in combination regimens.~* Patients must have received adequate alkylator therapy~Exclusion Criteria:~* Prior history of malignancies, other than Multiple Myeloma.~* Previous therapy with Pomalidomide, hypersensitivity to thalidomide and lenalidomide or dexamethasone.~* Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant.~* Patients who are planning for or who are eligible for stem cell transplant.~* Patients who received major surgery and any anti-myeloma drug therapy within the last 14 days of starting study treatment.~* Patients with a current disease that can interfere with protocol procedures or study treatment.~* Patients unable or unwilling to undergo antithrombotic prophylactic treatment.~* Pregnant or breastfeeding females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide plus Dexamethasone (Type: EXPERIMENTAL): Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have had documented multiple myeloma~* Must have received at least 1 prior line of therapy for multiple myeloma~* Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen~* Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2~* Must have achieved a response (partial response \[PR\] or better based on investigator's determination of response by the IMWG criteria) to at least 1 prior regimen in the past~Exclusion Criteria:~* Has received daratumumab or other anti-CD38 therapies previously~* Is refractory to VELCADE or another PI, like ixazomib and carfilzomib (had progression of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy or another PI therapy, like ixazomib and carfilzomib~* Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE treatment)~* Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day \[mg/day\] for a maximum of 4 days) before treatment. A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is provided in the Site Investigational Product Procedures Manual (IPPM).~* Has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization~* Has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab+VELCADE+dexamethasone (Type: EXPERIMENTAL): Daratumumab, VELCADE and dexamethasone
- VELCADE+dexamethasone (Type: ACTIVE_COMPARATOR): VELCADE and dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to initiation of any study-mandated procedure.~* Patients with pulmonary arterial hypertension and having completed the event-driven study, AC 055 302/SERAPHIN, or Patients who have experienced a clinical worsening of PAH in AC 055 302/SERAPHIN and for whom a written approval to roll over into this study has been obtained from the Sponsor.~* Women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination.~Exclusion Criteria:~* Any major violation of protocol AC 055 302/SERAPHIN.~* Pregnancy or breast-feeding.~* AST and/or ALT \> 3 times the upper limit of the normal range.~* Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.~* Known hypersensitivity to ACT 064992 or any of the excipients.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACT-064992 (Type: EXPERIMENTAL): ACT-064992

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Outcome in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 60 years or more~* de novo AML according to FAB criteria~* AML with 20% or more myeloid marrow blasts~* signed and dated informed consent~* OMS score \< 3~* Life expectancy \> 1 month~Exclusion Criteria:~* Patients aged \< 60 years~* or AML M3~* or not classificated according to FAB criteria~* or extramedular localisation of AML~* OMS score ≥ 3~* clinical Abnormal Cardiac fonction or with left ejection fraction \< 40 %~* abnormal renal function with creatinine clearance \< 50/ml/mn/m²~* abnormal hepatic function~* previous cerebral stroke~* previous malignancy : prostate, breast cancer (males)~* PSA dosage \> 4~* Any coexisting medical or psychological condition that would pleclude participation in the required study procedures

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): * Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  -idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.
- A (Type: EXPERIMENTAL): * Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  * idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~ * 10 to 20 mg (according to body weigh) of norethandrolone daily~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease (ESRD) without prior sensitization (defined as Panel Reactive Antibody \[PRA\] greater than 20%) within the 60 days prior to transplant as measured by cytotoxicity assays, ELISA, and flow cytometry;~* Undergoing a first or second transplant;~* Receiving a transplant from a living related donor who is ABO (blood type) compatible and haploidentical (3, 4, or 5 antigen match by serologic typing);~* Cardiac ejection fraction greater than 40%;~* Forced expiratory volume (FEV1) greater than 50%;~* Liver function tests, bilirubin, and coagulation studies less than 2 X normal;~* White blood cells greater than 2000/mm\^3; abd~* Platelets greater than 100,000/mm\^3~Exclusion Criteria:~* Positive donor lymphocyte cross-match;~* HIV-1 infected;~* Positive hepatitis B surface antigen (HbsAg);~* Hepatitis C virus infected;~* History of cancer;~* Prior dose-limiting radiation therapy;~* Pregnant, breastfeeding, or planning pregnancy within the time frame of the study;~* Enrolled in another investigational drug study within 30 days prior to study entry; or~* Receiving maintenance immunosuppression within 3 months before the conditioning regimen begins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Conditioning Regimen (Type: EXPERIMENTAL): Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven, untreated, locally advanced breast cancer; stage IIB (T3 N0), IIIA, or IIIB Measurable disease Not inflammatory breast cancer or other stage IIB (T2 N1) No distant metastases except for positive ipsilateral supraclavicular nodes~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant Fertile patients must use effective contraception during and 6 months after treatment Medically and psychologically stable~PRIOR CONCURRENT THERAPY: No prior therapy of any type

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 years of age or older~* Diagnosed of having hypertension, defined as a mean seated systolic BP ≥160 mmHg (Stage 2 hypertension)~Exclusion Criteria:~* Symptomatic or severe hypertension~* Patients treated with more than 2 antihypertensive medications~* Clinically known or suspected history of secondary hypertension~* Myocardial infarction, stroke, transient ischemic attack, cardiovascular revascularization/angioplasty in last 6 months~* Diagnosis of heart failure (NYHA Class II-IV)~* Chronic renal or severe hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 65 years or older on the day of inclusion~Exclusion Criteria:~* Febrile illness (oral temperature ≥37.5°C) on the day of inclusion~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination~* Unstable chronic illness~* Congenital or acquired immunodeficiency,~* Any blood or blood-derived product in the past 3 months~* Current abuse of alcohol or drug addiction~* Any vaccination in the past 4 weeks or planned in the 4 weeks following study vaccination~* Any vaccination against influenza in the past 6 months~* Subjects who previously received a vaccination against influenza by intradermal route

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Inactivated Split-Virion Influenza Vaccine for Intradermal Route
- 2 (Type: ACTIVE_COMPARATOR): Inactivated adjuvanted Influenza Vaccine for Intramuscular Route

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. 18 years or older~2. Clinical diagnosis of XLH~3. TmP/GFR \< 2.0 mg/dL~4. GFR ≥60 mL/min~5. Corrected Ca \<10.8 mg/dL~6. A willingness to utilize adequate contraception and not become pregnant\[or to have their partner(s) become pregnant\] during the study~7. Additional inclusion criteria apply~Main Exclusion Criteria:~1. Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within 3-weeks of Screening~2. History of known immunodeficiency~3. Pregnant or lactating females subjects or female planning to be become pregnant during the study~4. Receipt of a live (attenuated) vaccine (except for influenza vaccines) within 3-months of Screening, and/or during the study~5. Use of pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10-days prior to Screening and/or dosing~6. Use of any supplement containing phosphate, calcium and/or vitamin D within 10-days prior to Screening and/or dosing~7. Condition which could present a concern for either the subject's safety or difficulty with data interpretation~8. Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete